# The efficacy and safety of mirabegron and α-adrenergic receptor antagonist in the treatment of distal ureteral stones: a systematic review and meta-analysis

## TL;DR

This study compares mirabegron and α-adrenergic receptor antagonists for treating kidney stones and finds mirabegron reduces pain with fewer side effects.

## Contribution

The study provides a meta-analysis comparing mirabegron and α-adrenergic receptor antagonists for distal ureteral stone treatment, highlighting pain reduction and safety advantages.

## Key findings

- Mirabegron significantly reduced pain episodes compared to α-adrenergic receptor antagonists.
- Mirabegron had fewer side effects like headache and orthostatic hypotension.
- Pain reduction was more notable when mirabegron was compared to silodosin.

## Abstract

To systematically evaluate the efficacy and safety of mirabegron compared to α-adrenergic receptor antagonists for treating distal ureteral stones.

A comprehensive search of EMBASE, PubMed, and Cochrane databases was conducted to identify studies comparing mirabegron and α-adrenergic receptor antagonists for stone expulsion. The primary outcome was stone expulsion rate (SER), and secondary outcomes included stone expulsion interval (SEI) and pain episode frequency. Risk ratio (RR) and mean differences (MD) with 95% CIs were calculated.

Six studies involving 487 participants were included. There was no significant difference in SER between mirabegron and α-adrenergic receptor antagonists (RR = 1.06; 95% CI = 0.93–1.22; P = 0.34). SEI showed no significant difference either (MD = 0.05; 95% CI = −3.23 to 3.34; P = 0.58). However, pain episodes were significantly reduced in the mirabegron group (MD = −0.36; 95% CI = −0.63 to −0.09; P = 0.01). Subgroup analysis showed reduced pain episodes with mirabegron versus silodosin but not tamsulosin. Mirabegron also had fewer side effects like headache (RR = 0.34; 95% CI = 0.13–0.87; P = 0.02) and orthostatic hypotension (RR = 0.11; 95% CI = 0.02–0.55; P = 0.008), while dizziness and ejaculation dysfunction rates were comparable.

Mirabegron reduced pain episodes during treatment for distal ureteral stones, particularly when compared to silodosin, despite no significant differences in SER or SEI. Its favorable safety profile suggests potential as a therapeutic option. Further randomized controlled trials are needed to confirm these findings.